47
setting. Both Gram-negative and Gram-positive MDROs are prevalent globally (1, 2) . 48
There are few or no antimicrobial agents available for treatment of infections caused by 49 these bacteria (3). Pseudomonas aeruginosa, a Gram-negative, opportunistic pathogen 50 is a leading cause of nosocomial infections and is associated with infections in burn 51 patients (4, 5). P. aeruginosa is also responsible for colonizing the respiratory tract and 52 causing chronic infections in individuals with cystic fibrosis (CF) (6). It is the most 53 common pathogen isolated from individuals with CF, and is a major source of morbidity 54 and mortality (7) (8) (9) (10) . 55
56
In CF patients, P. aeruginosa undergoes a transformation from a non-mucoid form upon 57 initial colonization of the lungs to a mucoid form as the disease progresses. This results 58 in a chronic debilitating pulmonary infection characterized by the overexpression of 59 alginate. Mucoid strains synthesize large quantities of alginate exopolysaccharide, 60 enhancing biofilm formation and protecting P. aeruginosa from antibiotics or the immune 61 response (11), possibly through formation of microcolonies (12, 13) . While aggressive 62 prevention regimens have led to a decline in prevalence of P. aeruginosa in CF 63 patients, multidrug resistant strains are still prevalent and occurred in 19.4% of CF 64 infections in 2015 (14) . P. aeruginosa is inherently resistant to a number of antibiotics 65 (15, 16) . It can also acquire resistance through exogenous resistance genes via 66 horizontal gene transfer or mutations (17), limiting available treatment options. 67
Antimicrobial development is directed toward alternative treatments and novel targets. 68
Promising strategies include enhancing the activity of currently available antibiotics and 69 decreasing virulence of the bacteria once an infection occurs (18) (19) (20) (21) (22) (23) (24) (25) . 70 71 P. aeruginosa virulence is caused by many factors, including production of toxins, 72 proteases, phospholipases, the presence of pili and flagella, and biofilm formation (26) . 73
This virulence is regulated by a network of transcription factors, such as sigma factors 74
RpoS and RpoN, and quorum sensing regulators (27) . The alternative sigma factor,  54 75 or RpoN, regulates nitrogen assimilation, quorum sensing, motility, and biofilm formation 76 (28-33). RpoN regulation was recently linked to P. aeruginosa tolerance to several 77 antibiotics (34) (35) (36) . RpoN binds to specific promoters with conserved -24, -12 78 sequences upstream of RpoN-regulated genes throughout the genome and is a key 79 virulence regulator (37). The specific and conserved nature through which RpoN 80 controls its regulon led us to develop the RpoN molecular roadblock, RpoN*. RpoN* is 81 a cis-acting peptide that specifically binds the -24 site of RpoN consensus promoters, 82 blocking transcription by RpoN and other factors (38) . When RpoN* is expressed in P. 83 aeruginosa laboratory strains, transcription is affected globally and virulence is 84 attenuated (38). RpoN* also affects virulence in an RpoN deletion strain of P. 85 aeruginosa PAO1, demonstrating its ability to attenuate gene expression by repressing 86 expression of genes located downstream of RpoN promoters (38). This strategy of 87 blocking multiple promoters throughout the P. aeruginosa genome may be an effective 88 method to combat virulence and evade development of resistance. 89 90 5 P. aeruginosa isolated from CF patients are phenotypically and genetically varied (39, 91 40). Many P. aeruginosa clinical isolates have mutations, including deletion or loss of 92 function, in the rpoN gene (41, 42). It was not known how the cis-acting RpoN* peptide 93 would affect virulence phenotypes in P. aeruginosa clinical isolates, particularly in 94 strains that do not express or have low levels of RpoN. In this study, we describe the 95 effects of RpoN* on in vitro and in vivo virulence of P. aeruginosa isolated from CF 96 patients and its effects on antibiotic resistance. Expression of RpoN* reduced virulence-97 associated phenotypes in clinical isolates and improved P. aeruginosa susceptibility to 98 multiple antibiotics. This study demonstrates that RpoN* has potential clinical 99 applications and potentially represents an effective strategy to combat both antibiotic 100 resistance and infections with P. aeruginosa in CF patients. 101 6 produced moderate biofilms, with SCH0254-118 migrating the furthest ( Fig 1B) and 114 forming the most extensive biofilm ( Fig 1C) . SCH0254-116, SCH0397-3, and UUH0202 115 did not form biofilms. 116
117
The pathogenesis of patient isolates was evaluated in a P. aeruginosa -C. elegans 118 infection model. All patient isolates were compared to E. coli OP50, an avirulent 119 negative control. SCH0057-7 was the most pathogenic in the paralytic killing assay, 120 which is mediated by hydrogen cyanide production (44, 45) ( Fig 2A) . Other strains were 121 moderately pathogenic, including SCH0256-1, SCH0354-1, SCH0397-3, and UUH0202. 122 SCH0057-7, SCH0338-58, and UUH0202 were highly pathogenic in the slow killing 123 assay, which mimics establishment and proliferation of an infection and is mediated by 124 the lasR, gacA, lemA, and ptsP genes (46), while UUH0201 was moderately pathogenic 125 ( Fig 2B) . As expected, the virulence-associated phenotypes of patient isolates varied 126 widely in vitro and in vivo. 127 128
RpoN protein levels varied among patient isolates: 129
Others reported that the rpoN gene was mutated or lost in approximately 20% of P. 130 aeruginosa isolates from CF patients (41). Loss or mutation in the rpoN gene can result 131 in phenotypes similar to those observed in the patient isolates evaluated here (29, 31, 132 32) . Thus, we evaluated relative protein levels of RpoN in these patient isolates by 133 western blot. RpoN levels were moderately high in the positive control P. aeruginosa 134 PAO1-S, while low or minimal protein levels were detected in the isogenic rpoN mutant 135 negative control (Fig 3) . The low level of background in the rpoN mutant is likely due to 7 nonspecific antibody binding. RpoN levels varied in the CF patient isolates, with high 137 levels in SCH0057-7, SCH0397-3, and UUH0201; intermediate levels in 138 SCH0338-58, and UUH0202; and low levels in SCH0254-23, SCH0254-118, SCH0256-139 1, SCH0354-1, SCH03269, and UUH0101. The effect of RpoN* expression on motility and biofilm formation in patient isolates was 144 not known. Unfortunately, some patient isolates could not be transformed, and so only 145 four isolates were evaluated for the effects of RpoN* expressed from a plasmid. 146 SCH0057-7, SCH0256-1, SCH0338-58, and SCH0354-1 were transformed with a 147 plasmid expressing RpoN* or the empty vector and selected with gentamicin. If RpoN* 148 affected transcription of virulence-related genes in different genetic backgrounds as 149 previously reported (38), we expected attenuation of virulence-related phenotypes in P. 150 aeruginosa CF patient isolates. RpoN* significantly reduced colony diameter in all four 151 patient isolates in the swimming motility assay (Student's t-test, ** p≤0.01, ***p≤0.0001) 152 ( Fig 4A) . RpoN* significantly reduced colony diameter in SCH0057-7, SCH0256-1, and 153 SCH0338-58 in the twitching motility assay (Student's t-test, ** p≤0.01, ***p≤0.0001) 154 ( Fig 4B) . Colony diameter varied widely in SCH0354-1 when RpoN* was expressed and 155 was always smaller than with empty vector, although the difference was not significant. 156
In the biofilm formation assay, RpoN* significantly reduced biofilm formation by 157 SCH0057-7 and SCH0256-1 (Student's t-test, p≤0.0001) ( Fig 4C) . Thus RpoN* reduced 158 virulence-associated phenotypes of P. aeruginosa isolated from CF patients. Antibiotic resistance is a problem in CF patients with P. aeruginosa infections (47-49). 178
We previously reported that RpoN* alters transcription of several genes involved in 179 multidrug efflux pumps that confer natural resistance (38). Additionally, RpoN is 180 implicated in tolerance to various classes of antibiotics (34-36). We evaluated the 181 effects of RpoN* on antibiotic susceptibility using a MicroScan Neg MIC 43 panel. The 182 test conditions were P. aeruginosa PA19660 Xen5 that was mock-transformed, or 183 transformed with the empty vector or RpoN* plasmid. We expected that RpoN* would 184 improve antibiotic susceptibility of P. aeruginosa. In PA19660 Xen5 mock-transformed 185 or with the empty vector, antibiotic susceptibility profiles were the same, except for 186 gentamicin, which increased in the empty vector strain due to the GM R selection marker 187 (data not shown). In PA19660 Xen5 expressing RpoN*, susceptibility to five beta-lactam 188 antibiotics was improved 2-to 4-fold ( Fig 6) . These were cefotaxime, cefepime, and 189 ceftazidime (three cephalosporins), piperacillin (a ureidopenicillin), and imipenem (a 190 carbapenem). Susceptibility to some antibiotics was unchanged (data not shown). There was no correspondence between most in vitro phenotypes, in vivo pathogenesis, 211
and RpoN levels (Fig. S1 ). The only correlation observed was between twitching or pili-212 associated motility and biofilm formation (Supplemental Fig 1F, p=0 .0357, R 2 =0.37050). 213
Other studies suggested that in vitro phenotypes of P. aeruginosa isolates can be 214 related to disease status in CF patients (50). Patient information and status of P. 215 aeruginosa infections is limited for the isolates described here, so a comparison 216 between phenotypes and patient status is not feasible. Interestingly, two isolates, 217 UUH0201 and UUH0202, were obtained five months apart from the same patient, with 218 UUH0201 collected first. The UUH0202 strain was less motile and RpoN protein levels 219 dropped compared to UUH0201, but virulence increased. This supports the concept that 220 in vitro phenotypes reflect P. aeruginosa infection status in CF patients (50). Further 221 work would be needed to fully elucidate such correlations. 222
223
The RpoN* molecular roadblock reduced virulence phenotypes in patient isolates with 224 high or low levels of RpoN. For instance, RpoN protein levels were higher in SCH0057-225 7 than PAO1-S, and RpoN* reduced flagellar and pili motility, biofilm formation and 226 pathogenesis. In contrast, relative RpoN protein levels were low in SCH0256-1 and 227 SCH0354-1, and yet RpoN* reduced motility. Thus, the roadblock was effective in the 228 presence or absence of the native sigma factor. This confirms our previous findings, 229 which show that RpoN* reduced virulence in a laboratory strain that was deleted for 230 rpoN (38). Unfortunately, barriers to transformation precluded evaluating RpoN* in some 231 of the other clinical isolates. However, the strains that were successfully transformed 232
represented much of the diversity across the patient isolates. 233
234
The CF patient isolates demonstrated variable pathogenesis in the C. elegans paralytic 235 killing model that spans 6 hours. Only one pathogenic isolate, SCH0057-7, was 236 transformable and thus possible to evaluate the effects of RpoN* in vivo. This strain 237
and several others were also pathogenic in the 4-day slow killing assay, but this assay 238
was not used to evaluate RpoN* because of difficulty maintaining the plasmid and 239 RpoN* expression. Gentamicin selection and IPTG induction are not durable, we found 240 (38), because the C. elegans cuticle is impermeable and the compounds are poorly 241 absorbed in the intestine (51). While it is expected that expressing RpoN* in CF 242
isolates would improve C. elegans survival in the slow killing assay, it is not feasible 243 with the current vector. If issues with maintaining the plasmid and expression of the 244 roadblock were resolved, it would be interesting to evaluate RpoN* in this assay using 245 patient isolates. 246
247
The molecular roadblock, RpoN*, binds numerous promoters in bacterial genomes, 248 altering the transcriptome. RpoN* expression in P. aeruginosa greatly reduced 249 transcription of the mex family genes (38), which are involved in multidrug efflux pumps 250 (20). Increased expression of mex genes is linked to increased resistance to antibiotics 251 (17). Therefore, we investigated whether RpoN* alters P. aeruginosa susceptibility to 252 antibiotics. We employed a clinical laboratory assay for testing bacterial susceptibility or 253 resistance to antibiotics, and found that RpoN* improved antibiotic susceptibility at least 254 two-fold for five different antibiotics, including imipenem. This agrees with work by 255 others that showed RpoN is involved in P. aeruginosa tolerance of carbapenems, 256 quinolones, and tobramycin (34-36). Unfortunately, the commercial assay uses pre-257 determined antibiotic concentrations in a 96-well plate, limiting the scope of the 258 molecular roadblock's effects. Additionally, the P. aeruginosa strain used here is 259 sensitive to quinolones and tobramycin, so the effects of RpoN* expression on 260 resistance to these antibiotics was not evaluated. It will be important to test clinical 261 strains that are resistant to quinolones, carbapenems, and tobramycin to determine the 262 effects of RpoN*. Further studies are needed to uncover the full spectrum of RpoN* 263 effects on antibiotic susceptibility. 264
265
Multi-drug resistant organisms (MRDOs) are increasing worldwide, even those with 266 resistance to entire classes of antibiotics. Alarmingly, nearly all antibiotics brought to 267 market in the past 30 years are variations on existing drugs (52). Research into 268 alternative strategies to treat bacterial infections is a priority, including compounds to 269 enhance the activity of existing antibiotics or neutralize virulence factors. The molecular 270 roadblock falls into the latter type. RpoN* binds consensus promoters throughout the P. 271 aeruginosa genome, affecting the transcription of numerous virulence factors. Due to 272 the many binding sites for RpoN*, it is unlikely antibiotic resistance will develop during 273 13 treatment. The binding sequence of the RpoN consensus promoter is conserved across 274 gram-negative and gram-positive bacteria (36, 37) . We explored the effects of RpoN* 275 on virulence phenotypes of Pseudomonas putida, Burkholderia cepacia, and 276
Escherichia coli (unpublished data), suggesting that RpoN* may reduce virulence in 277 multiple organisms. More studies are needed to identify the spectrum of RpoN* activity 278 and its resistance frequency. Currently, the molecular roadblock is a tool for 279 antimicrobial development and is not a usable drug. However, a small molecule that 280 works in the same cis-acting manner as RpoN* would be an effective, clinically relevant 281 strategy to combat P. aeruginosa virulence and antibiotic resistance. 
P. aeruginosa -C. elegans infection assays: 332
For the paralytic killing assay, laboratory strains, clinical isolates, or transformed P. 333 aeruginosa were spread on Brain Heart Infusion (BHI) agar (Difco) with, when 334 applicable, gentamicin (30 mg/L) and with or without IPTG (1 mM). E. coli was spread 335 on BHI agar. All plates were grown overnight at 37°C. Bacteria colonies were swabbed 336 onto BHI agar, supplemented with gentamicin and/or IPTG (1 mM) when applicable, 337 and grown at 37°C for 24 h (44). Adult C. elegans were added to plates and the assay 338 was conducted at room temperature, per standard protocol (44). For the slow killing 339 assay, laboratory strains or clinical isolates of P. aeruginosa were grown overnight in LB 340 broth at 37°C with shaking, and cultures were spread on a modified NGM agar (0.35% 341 bactopeptone, 2% bactoagar) (58). Plates were incubated at 37°C for 24 h, then at 342 room temperature for an additional 24 h. The assay was conducted at 20°C, and worms 343 were scored every 24 h per standard protocol (58) . The datasets produced for the current study are included in this manuscript or are 364 available from the corresponding author upon reasonable request. 365 366 Acknowledgements 367
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